Fig. 1From: CD16 expression on neutrophils predicts treatment efficacy of capecitabine in colorectal cancer patientsCD16 expression of peripheral blood myeloid cells were differential in CRC patients after capecitabine therapy. Peripheral venous blood from CRC patients received single-agent oral capecitabine adjuvant therapy was collected before the therapy and 6–9 months after the therapy and analyzed for myeloid cell-related markers. (Attention: Blood were collected 6–9 months after capecitabine treatment unless particularly noted). a Frequencies of CD11b+CD16+myeloid cells were compared before and after capecitabine therapy in capecitabine-sensitive and capecitabine-resistant patients (n = 26 in sensitive group and n = 10 in resistant group, respectively). b Representative images of CD16 expression on CD11b+myeloid cells before and after capecitabine therapy in two CRC patients from capecitabine-sensitive group or capecitabine resistant group, respectively. Diagnosis of drug-resistance was proved by CT scan during the follow-up in Fig. S1e. Mean ± SEM, *P<0.05 by t tests (a)Back to article page